Physicochemical Properties and Factors that Induce Asbestos-Related Respiratory Disease
Source abstract
Abstract
It is thought that inhaled dusts such as asbestos and man-made mineral fibers in the lung repeatedly induce persistent inflammation and finally lead to pulmonary fibrosis and respiratory cancer. There have been many studies about whether a variety of factors, such as oxidative stress including free radicals, chemokines, inflammatory cytokines, and fibrosis-related cytokines are related to pulmonary fibrosis, lung cancer and malignant mesothelioma. In this paper, we introduce the relationship between these factors and these diseases. It is important to determine what physicochemical properties of fibrous materials such as asbestos are related to asbestos-related diseases. We show the relationship between the physicochemical properties of not only asbestos but also other fibrous materials and inflammation, fibrosis and biopersistence in the lung.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Occupational and environmental lung diseases · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Biomarkers in Disease Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health
References (94)
Show source-provided references
1. 1) The comittee report on the regulation for authorization of asbestos-related disease. (2012): Ministry of Health, Labour and Welfare.
2. 2) Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. (1997): Scand J Work Environ Health 23, pp. 311–316.10.5271/sjweh.226 ↗
3. 3) Henderson, D. W. and Leigh, J. (2011): “Chapter 6. Asbestos and Carcinoma of the Lung. In: Dodson, R. F., Hammar, S. P., (eds.), Asbestos. Risk assessment, epidemiology and health effects, second edition”, CRC press, pp. 269–306.
4. 4) Kurumatani, N. and Kumagai, S. (2008): Mapping the risk of mesothelioma due to neighborhood asbestos exposure, American Journal of Respiratory and Critical Care Medicine, Vol. 178, pp. 624–629.10.1164/rccm.200801-063OC ↗
5. 5) Hodgson, J. T. and Darnton, A. (2000): The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure, Annals of Occupational Hygiene, Vol. 44, pp. 565–601.10.1016/S0003-4878(00)00045-4 ↗
6. 6) IARC monographs on the evaluation of carcinogenic risks to humans. Volume 81 Man-made vitreous fibres. (2002): IARC press
7. 7) Mossman, B. T., Lippmann, M., Hesterberg, T. W., Kelsey, K. T., Barchowsky, A. and Bonner, J. C. (2011): Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos, Journal of Toxicology and Environmental Health. Part B, Critical Reviews, Vol. 14, pp. 76–121.10.1080/10937404.2011.556047 ↗
8. 8) Ardies, C. M. (2003): Inflammation as cause for scar cancers of the lung, Integrative Cancer Therapies, Vol. 2, pp. 238– 246.10.1177/1534735403256332 ↗
9. 9) Ogami, A., Morimoto, Y., Myojo, T., Oyabu, T., Murakami, M., Nishi, K., Kadoya, C. and Tanaka, I. (2007): Histopathological changes in rat lung following intratracheal instillation of silicon carbide whiskers and potassium octatitanate whiskers, Inhalation Toxicology, Vol. 19, pp. 753–758.10.1080/08958370701399869 ↗
10. 10) Quinlan, T. R., BéruBé, K. A., Marsh, J. P., Janssen, Y. M., Taishi, P., Leslie, K. O., Hemenway, D., O’Shaughnessy, P. T., Vacek, P. and Mossman, B. T. (1995): Patterns of inflammation, cell proliferation, and related gene expression in lung after inhalation of chrysotile asbestos, American Journal of Pathology, Vol. 147, pp. 728–739.
11. 11) Roberts, R. A., Smith, R. A., Safe, S., Szabo, C., Tjalkens, R. B. and Robertson, F. M. (2010): Toxicological and pathophysiological roles of reactive oxygen and nitrogen species, Toxicology, Vol. 276, pp. 85–94.10.1016/j.tox.2010.07.009 ↗
12. 12) Gius, D. and Spitz, D. R. (2006): Redox signaling in cancer biology, Antioxidants & Redox Signaling, Vol. 8, pp. 1249– 1252.10.1089/ars.2006.8.1249 ↗
13. 13) Fubini, B. and Hubbard, A. (2003): Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis, Free Radical Biology & Medicine, Vol. 34, pp. 1507–1516.10.1016/S0891-5849(03)00149-7 ↗
14. 14) Dizdaroglu, M. and Jaruga. P. (2012): Mechanisms of free radical-induced damage to DNA, Free Radical Research. Vol. 46, pp. 382–419.10.3109/10715762.2011.653969 ↗
15. 15) Hawkins, C. L., Morgan, P. E. and Davies, M. J. (2009): Quantification of protein modification by oxidants, Free Radical Biology & Medicine, Vol. 46, pp. 965–988.10.1016/j.freeradbiomed.2009.01.007 ↗
16. 16) Fialkow, L., Wang, Y. and Downey, G. P. (2007): Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function, Free Radical Biology & Medicine, Vol. 42, pp. 153–164.10.1016/j.freeradbiomed.2006.09.030 ↗
17. 17) Kar, S., Subbaram, S., Carrico, P. M. and Melendez, J. A. (2010): Redox-control of matrix metalloproteinase-1: a critical link between free radicals, matrix remodeling and degenerative disease, Respiratory Physiology & Neurobiology, Vol. 174, pp. 299–306.10.1016/j.resp.2010.08.019 ↗
18. 18) Kliment, C. R. and Oury, T. D. (2010): Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis, Free Radical Biology & Medicine, Vol. 49, pp. 707–717.10.1016/j.freeradbiomed.2010.04.036 ↗
19. 19) Chan, E. C., Jiang, F., Peshavariya, H. M. and Dusting, G. J. (2009): Regulation of cell proliferation by NADPH oxidase-mediated signaling: potential roles in tissue repair, regenerative medicine and tissue engineering, Pharmacology & Therapeutics, Vol. 122, pp. 97–108.10.1016/j.pharmthera.2009.02.005 ↗
20. 20) Azad, N., Iyer, A., Vallyathan, V., Wang, L., Castranova, V., Stehlik, C. and Rojanasakul, Y. (2010): Role of oxidative/nitrosative stress-mediated Bcl-2 regulation in apoptosis and malignant transformation, Annals of the New York Academy of Sciences, Vol. 1203, pp. 1–6.10.1111/j.1749-6632.2010.05608.x ↗
21. 21) Liu, G., Cheresh, P. and Kamp, D. W. (2013): Molecular basis of asbestos-induced lung disease, Annual Review of Pathology, Vol. 8, pp. 161–187.10.1146/annurev-pathol-020712-163942 ↗
22. 22) Kido, T., Morimoto, Y., Asonuma, E., Yatera, K., Ogami, A., Oyabu, T., Tanaka, I. and Kido, M. (2008): Chrysotile asbestos causes AEC apoptosis via the caspase activation in vitro and in vivo, Inhalation Toxicology, Vol. 20, pp. 339–347.10.1080/08958370701866362 ↗
23. 23) Was, H., Dulak, J. and Jozkowicz, A. (2010): Heme oxygenase-1 in tumor biology and therapy, Current Drug Targets, Vol. 11, pp. 1551–1570.10.2174/1389450111009011551 ↗
24. 24) Raval, C. M. and Lee, P. J. (2010): Heme oxygenase-1 in lung disease, Current Drug Targets, Vol. 11, pp. 1532–1540.10.2174/1389450111009011532 ↗
25. 25) Nagatomo, H., Morimoto, Y., Oyabu, T., Hirohashi, M., Ogami, A., Yamato, H., Kuroda, K., Higashi, T. and Tanaka, I. (2005): Expression of heme oxygenase-1 in the lungs of rats exposed to crocidolite asbestos, Inhalation Toxicology, Vol. 17, pp. 293–296.10.1080/08958370590922580 ↗
26. 26) Nagatomo, H., Morimoto, Y., Ogami, A., Hirohashi, M., Oyabu, T., Kuroda, K., Higashi, T. and Tanaka, I. (2007): Change of heme oxygenase-1 expression in lung injury induced by chrysotile asbestos in vivo and in vitro, Inhalation Toxicology, Vol. 19, pp. 317–323.10.1080/08958370601144167 ↗
27. 27) Driscoll, K. E., Carter, J. M., Howard, B. W., Hassenbein, D., Janssen, Y. M. and Mossman, B. T. (1998): Crocidolite activates NF-kappa B and MIP-2 gene expression in rat alveolar epithelial cells. Role of mitochondrial-derived oxidants, Environmental Health Perspectives, Vol. 5, pp. 1171– 1174.10.1289/ehp.98106s51171 ↗
28. 28) Fattman, C. L., Tan, R. J., Tobolewski, J. M. and Oury, T. D. (2006): Increased sensitivity to asbestos-induced lung injury in mice lacking extracellular superoxide dismutase, Free Radical Biology & Medicine, Vol. 40, pp. 601–607.10.1016/j.freeradbiomed.2005.09.030 ↗
29. 29) Murata, M., Thanan, R., Ma, N. and Kawanishi, S. (2012): Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis, Journal of Biomedicine & Biotechnology, Vol. 2012, Article ID.623019. doi: 10.1155/2012/623019.10.1155/2012/623019 ↗
30. 30) Hiraku, Y., Kawanishi, S., Ichinose, T. and Murata, M. (2010): The role of iNOS-mediated DNA damage in infection- and asbestos-induced carcinogenesis, Annals of the New York Academy of Sciences, Vol. 1203, pp. 15–22.10.1111/j.1749-6632.2010.05602.x ↗
31. 31) Matsuoka, M., Igisu, H. and Morimoto, Y. (2003): Phosphorylation of p53 protein in A549 human pulmonary epithelial cells exposed to asbestos fibers, Environmental Health Perspectives, Vol. 111, pp. 509–512.10.1289/ehp.5945 ↗
32. 32) Mineo, T. C. and Ambrogi, V. (2012): Malignant pleural mesothelioma: factors influencing the prognosis, Oncology, Vol. 26, pp. 1164–1175.
33. 33) Chiba, T., Marusawa, H. and Ushijima, T. (2012): Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation, Gastroenterology, Vol. 143, pp. 550–563.10.1053/j.gastro.2012.07.009 ↗
34. 34) Wen, J., Fu, J., Zhang, W. and Guo, M. (2011): Genetic and epigenetic changes in lung carcinoma and their clinical implications, Modern Pathology, Vol. 24, pp. 932–943.10.1038/modpathol.2011.46 ↗
35. 35) Risch, A. and Plass, C. (2008): Lung cancer epigenetics and genetics, International Journal of Cancer, Vol. 123, pp. 1–7.10.1002/ijc.23605 ↗
36. 36) Suda, K., Tomizawa, K. and Mitsudomi, T. (2010): Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation, Cancer Metastasis Reviews, Vol. 29, pp. 49–60.10.1007/s10555-010-9209-4 ↗
37. 37) Bean, G. R., Ganesan, Y. T., Dong, Y., Takeda, S., Liu, H., Chan, P. M., Huang, Y., Chodosh, L. A., Zambetti, G. P., Hsieh, J. J. and Cheng, E. H. (2013): PUMA and BIM are required for oncogene inactivation-induced apoptosis, Science Signaling, Vol. 6, pp.:ra20. doi: 10.1126/scisignal.2003483.10.1126/scisignal.2003483 ↗
38. 38) Ahrendt, S. A., Decker, P. A., Alawi, E. A., Zhu, Yr. YR., Sanchez-Cespedes, M., Yang, S. C., Haasler, G. B., Kajdacsy-Balla, A., Demeure, M. J. and Sidransky, D. (2001): Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung, Cancer, Vol. 92, pp. 1525–1530.10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H ↗
39. 39) Sioris, T., Husgafvel-Pursiainen, K., Karjalainen, A., Anttila, S., Kannio, A., Salo, J. A., Perhoniemi, V., Heikkilä, L. and Vainio, H. (2000): Survival in operable non-small-cell lung cancer: role of p53 mutations, tobacco smoking and asbestos exposure, International Journal of Cancer, Vol. 86, pp. 590–594.10.1002/(SICI)1097-0215(20000515)86:4<590::AID-IJC23>3.0.CO;2-E ↗
40. 40) Nelson, H. H., Christiani, D. C., Wiencke, J. K., Mark, E. J., Wain, J. C. and Kelsey, K. T. (1999): k-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis, Cancer Research, Vol. 59, pp. 4570–4573.
41. 41) Mayall, F. G., Jacobson, G. and Wilkins, R. (1999): Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas, Journal of Clinical Pathology, Vol. 52, pp. 291–293.10.1136/jcp.52.4.291 ↗
42. 42) Husgafvel-Pursiainen, K., Karjalainen, A., Kannio, A., Anttila, S., Partanen, T., Ojajärvi, A. and Vainio, H. (1999): Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations, American Journal of Respiratory Cell and Molecular Biology, Vol. 20, pp. 667–674.10.1165/ajrcmb.20.4.3404 ↗
43. 43) Liu, B. C., Fu, D. C., Miao, Q., Wang, H. H. and You, B. R. (1998) p53 gene mutations in asbestos associated cancers, Biomedical and environmental sciences, Vol. 11, pp. 226– 232.
44. 44) Husgafvel-Pursiainen, K., Kannio, A., Oksa, P., Suitiala, T., Koskinen, H., Partanen, R., Hemminki, K., Smith, S., Rosenstock-Leibu, R. and Brandt-Rauf, P. W. (1997): Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure, Environmental and Molecular Mutagenesis, Vol. 30, pp. 224–230.10.1002/(SICI)1098-2280(1997)30:2<224::AID-EM15>3.3.CO;2-D ↗
45. 45) Kannio, A. (1996): A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking, and occupational exposure to asbestos, Cancer Epidemiology, Biomarkers & Prevention, Vol. 5, pp. 33–39.
46. 46) Wang, X., Christiani, D. C., Wiencke, J. K., Fischbein, M., Xu, X., Cheng, T. J., Mark, E., Wain, J. C. and Kelsey, K. T. (1995): Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure, Cancer Epidemiology, Biomarkers & Prevention, Vol. 4, pp. 543– 548.
47. 47) Vainio, H., Husgafvel-Pursiainen, K., Anttila, S., Karjalainen, A., Hackman, P. and Partanen, T. (1993): Interaction between smoking and asbestos in human lung adenocarcinoma: role of K-ras mutations, Environmental Health Perspectives, Vol. 3, pp. 189–192.10.1289/ehp.93101s3189 ↗
48. 48) Husgafvel-Pursiainen, K., Hackman, P., Ridanpää, M., Anttila, S., Karjalainen, A., Partanen, T., Taikina-Aho, O., Heikkilä, L. and Vainio, H. (1993): K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos, International Journal of Cancer, Vol. 53, pp. 250–256.10.1002/ijc.2910530213 ↗
49. 49) Muller, P. A. and Vousden, K. H. (2013): p53 mutations in cancer, Nature Cell Biology, Vol. 15, pp. 2–8.10.1038/ncb2641 ↗
50. 50) Nymark, P., Wikman, H., Ruosaari, S., Hollmén, J., Vanhala, E., Karjalainen, A., Anttila, S. and Knuutila, S. (2006): Identification of specific gene copy number changes in asbestos-related lung cancer, Cancer Research, Vol. 66, pp. 5737–5743.10.1158/0008-5472.CAN-06-0199 ↗
51. 51) Wikman, H., Ruosaari, S., Nymark, P., Sarhadi, V. K., Saharinen, J., Vanhala, E., Karjalainen, A., Hollmén, J., Knuutila, S. and Anttila, S. (2007): Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer, Oncogene, Vol. 26, pp. 4730–4737.10.1038/sj.onc.1210270 ↗
52. 52) Nymark, P., Kettunen, E., Aavikko, M., Ruosaari, S., Kuosma, E., Vanhala, E., Salmenkivi, K., Pirinen, R., Karjalainen, A., Knuutila, S., Wikman, H. and Anttila, S. (2009): Molecular alterations at 9q33.1 and polyploidy in asbestos-related lung cancer, Clinical Cancer Research, Vol. 15, pp. 468–475.10.1158/1078-0432.CCR-08-1852 ↗
53. 53) Kettunen, E., Aavikko, M., Nymark, P., Ruosaari, S., Wikman, H., Vanhala, E., Salmenkivi, K., Pirinen, R., Karjalainen, A., Kuosma, E. and Anttila, S. (2009): DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure, British Journal of Cancer, Vol. 100, pp. 1336–1342.10.1038/sj.bjc.6605012 ↗
54. 54) Palumbo, E., Tosoni, E., Matricardi, L. and Russo, A. (2013): Genetic instability of the tumor suppressor gene FHIT in normal human cells, Genes, Chromosomes & Cancer, Vol. 52, pp. 832–844.10.1002/gcc.22079 ↗
55. 55) Nelson, H. H., Wiencke, J. K., Gunn, L., Wain, J. C., Christiani, D. C. and Kelsey, K. T. (1998): Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos, Cancer Research, Vol. 58, pp. 1804–1807.
56. 56) Pylkkanen, L., Wolff, H., Stjernvall, T., Tuominen, P., Sioris, T., Karjalainen, A., Anttila, S. and Husgafvel-Pursiainen, K., (2002): Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients, International Journal of Oncology, Vol. 20, pp. 285–290.
57. 57) Metcalf, R. A., Welsh, J. A., Bennett, W. P., Seddon, M. B., Lehman, T. A., Pelin, K., Linnainmaa, K., Tammilehto, L., Mattson, K., Gerwin, B. I. and Harris, C. C. (1992): p53 and Kirsten-ras mutations in human mesothelioma cell lines, Cancer Research, Vol. 52, pp. 2610–2615.
58. 58) Mezzapelle, R., Miglio, U., Rena, O., Paganotti, A., Allegrini, S., Antona, J., Molinari, F., Frattini, M., Monga, G., Alabiso, O. and Boldorini, R. (2013): Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma, British Journal of Cancer, Vol. 108, pp. 1743–1749.10.1038/bjc.2013.130 ↗
59. 59) Ventii, K. H., Devi, N. S., Friedrich, K. L., Chernova, T. A., Tighiouart, M., Van Meir, E. G. and Wilkinson, K. D. (2008): BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization, Cancer Research, Vol. 68, pp. 6953–6962.10.1158/0008-5472.CAN-08-0365 ↗
60. 60) Murali, R., Wiesner, T. and Scolyer, R. A. (2013): Tumours associated with BAP1 mutations, Pathology, Vol. 45, pp. 116–126.10.1097/PAT.0b013e32835d0efb ↗
61. 61) Li, J., Poi, M. J. and Tsai, M. D. (2011): Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer, Biochemistry, Vol. 50, pp. 5566–5582.10.1021/bi200642e ↗
62. 62) Rayess, H., Wang, M. B. and Srivatsan, E. S. (2012): Cellular senescence and tumor suppressor gene p16, International Journal of Cancer, Vol. 130, pp. 1715–1725.10.1002/ijc.27316 ↗
63. 63) Harvey, K. F., Zhang, X. and Thomas, D. M. (2013): The Hippo pathway and human cancer, Nature Reviews. Cancer, Vol. 13, pp. 246–257.10.1038/nrc3458 ↗
64. 64) Sekido, Y. (2013): Molecular pathogenesis of malignant mesothelioma, Carcinogenesis, Vol. 34, pp. 1413–1419.10.1093/carcin/bgt166 ↗
65. 65) Ladanyi, M., Zauderer, M. G., Krug, L. M., Ito, T., McMillan, R., Bott, M. and Giancotti, F. (2012): New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment, Clinical Cancer Research, Vol. 18, pp. 4485–4490.10.1158/1078-0432.CCR-11-2375 ↗
66. 66) Enomoto, Y., Kasai, T., Takeda, M., Takano, M., Morita, K., Kadota, E., Iizuka, N., Maruyama, H., Haratake, J., Kojima, Y., Ikeda, N., Inatsugi, N. and Nonomura, A. (2012): Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma, Journal of Clinical Pathology, Vol. 65, pp. 522–527.10.1136/jclinpath-2011-200631 ↗
67. 67) Okuda, K., Sasaki, H., Kawano, O., Yukiue, H., Yokoyama, T., Yano, M. and Fujii, Y. (2008): Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma, Journal of Cancer Research and Clinical Oncology, Vol. 134, pp. 1105–1111.10.1007/s00432-008-0384-4 ↗
68. 68) Rena, O., Boldorini, L. R., Gaudino, E. and Casadio, C. (2011): Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations, Journal of Surgical Oncology, Vol. 104, pp. 701–705.10.1002/jso.21901 ↗
69. 69) Destro, A., Ceresoli, G. L., Falleni, M., Zucali, P. A., Morenghi, E., Bianchi, P., Pellegrini, C., Cordani, N., Vaira, V., Alloisio, M., Rizzi, A., Bosari, S. and Roncalli, M. (2006): EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations, Lung Cancer, Vol. 51, pp. 207–215.10.1016/j.lungcan.2005.10.016 ↗
70. 70) Murthy, S. S. and Testa, J. R. (1999): Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma, Journal of Cellular Physiology, Vol. 180, pp. 150–157.10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H ↗
71. 71) Dawson, M. A. and Kouzarides, T. (2012): Cancer epigenetics: from mechanism to therapy, Cell, Vol. 150, pp. 12–27.10.1016/j.cell.2012.06.013 ↗
72. 72) Zhao, C. and Bu, X. (2012): Promoter methylation of tumor-related genes in gastric carcinogenesis, Histology and Histopathology, Vol. 27, pp. 1271–1282.
73. 73) Díez-Pérez, R., Campo-Trapero, J., Cano-Sánchez, J., López-Durán, M., Gonzalez-Moles, M. A., Bascones-Ilundain, J. and Bascones-Martinez, A. (2011): Methylation in oral cancer and pre-cancerous lesions (Review), Oncology Reports, Vol. 25, pp. 1203–1209.
74. 74) Phé, V., Cussenot, O. and Rouprêt, M. (2009): Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract, BJU International, Vol. 104, pp. 896–901.10.1111/j.1464-410X.2009.08696.x ↗
75. 75) Wentzensen, N., Sherman, M. E., Schiffman, M. and Wang, S. S. (2009): Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science, Gynecologic Oncology, Vol. 112, pp. 293–299.10.1016/j.ygyno.2008.10.012 ↗
76. 76) Dammann, R., Strunnikova, M., Schagdarsurengin, U., Rastetter, M., Papritz, M., Hattenhorst, U. E., Hofmann, H. S., Silber, R. E., Burdach, S. and Hansen, G. (2005): CpG island methylation and expression of tumour-associated genes in lung carcinoma, European Journal of Cancer, Vol. 41, pp. 1223–1236.10.1016/j.ejca.2005.02.020 ↗
77. 77) Fujii, M., Fujimoto, N., Hiraki, A., Gemba, K., Aoe, K., Umemura, S., Katayama, H., Takigawa, N., Kiura, K., Tanimoto, M. and Kishimoto, T. (2012): Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma, Cancer Science, Vol. 103, pp. 510–514.10.1111/j.1349-7006.2011.02180.x ↗
78. 78) Sawan, C. and Herceg, Z. (2010): Histone modifications and cancer, Advances in Genetics, Vol. 70, pp. 57–85.10.1016/B978-0-12-380866-0.60003-4 ↗
79. 79) Ramalingam, S. S. and Belani, C. P. (2008): Recent advances in the treatment of malignant pleural mesothelioma, Journal of Thoracic Oncology, Vol. 3, pp. 1056–1064.10.1097/JTO.0b013e3181834f66 ↗
80. 80) Maki, Y., Asano, H., Toyooka, S., Soh, J., Kubo, T., Katsui, K., Ueno, T., Shien, K., Muraoka, T., Tanaka, N., Yamamoto, H., Tsukuda, K., Kishimoto, T., Kanazawa, S. and Miyoshi, S. (2012): MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells, Anticancer Research, Vol. 32, pp. 4871–4875.
81. 81) Kirschner, M. B., Cheng, Y. Y., Badrian, B., Kao, S. C., Creaney, J., Edelman, J. J., Armstrong, N. J., Vallely, M. P., Musk, A. W., Robinson, B. W., McCaughan, B. C., Klebe, S., Mutsaers, S. E., van Zandwijk, N. and Reid, G. (2012): Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma, Journal of Thoracic Oncology, Vol. 7, pp. 1184–1191.10.1097/JTO.0b013e3182572e83 ↗
82. 82) Santarelli, L., Strafella, E., Staffolani, S., Amati, M., Emanuelli, M., Sartini, D., Pozzi, V., Carbonari, D., Bracci, M., Pignotti, E., Mazzanti, P., Sabbatini, A., Ranaldi, R., Gasparini, S., Neuzil, J. and Tomasetti, M. (2011): Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma, PLoS One, Vol. 6, e18232. DOI: 10.1371/journal.pone.0018232.10.1371/journal.pone.0018232 ↗
83. 83) Pass, H. I., Goparaju, C., Ivanov, S., Donington, J., Carbone, M., Hoshen, M., Cohen, D., Chajut, A., Rosenwald, S., Dan, H., Benjamin, S. and Aharonov, R. (2010): hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma, Cancer Research, Vol. 70, pp. 1916–1924.10.1158/0008-5472.CAN-09-3993 ↗
84. 84) Weber, D. G., Johnen, G., Bryk, O., Jöckel, K. H. and Brüning, T. (2012): Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential bio-marker for malignant mesothelioma – a pilot study, PLoS One, Vol. 7, e30221. DOI: 10.1371/journal.pone.0030221.10.1371/journal.pone.0030221 ↗
85. 85) Busacca, S., Germano, S., De Cecco, L., Rinaldi, M., Comoglio, F., Favero, F., Murer, B., Mutti, L., Pierotti, M. and Gaudino, G. (2010): MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications, American Journal of Respiratory Cell and Molecular Biology, Vol. 42, pp. 312–319.10.1165/rcmb.2009-0060OC ↗
86. 86) Tomasetti, M., Staffolani, S., Nocchi, L., Neuzil, J., Strafella, E., Manzella, N., Mariotti, L., Bracci, M., Valentino, M., Amati, M. and Santarelli, L. (2012): Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients, Clinical biochemistry, Vol. 45, pp. 575–581.10.1016/j.clinbiochem.2012.02.009 ↗
87. 87) Benjamin, H., Lebanony, D., Rosenwald, S., Cohen, L., Gibori, H., Barabash, N., Ashkenazi, K., Goren, E., Meiri, E., Morgenstern, S., Perelman, M., Barshack, I., Goren, Y., Edmonston, T.B., Chajut, A., Aharonov, R., Bentwich, Z., Rosenfeld, N. and Cohen, D. (2010): A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma, Journal of Molecular Diagnostics, Vol. 12, pp. 771–779.10.2353/jmoldx.2010.090169 ↗
88. 88) Khodayari, N., Mohammed, K. A., Goldberg, E. P. and Nasreen, N. (2011): EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene, Cancer Gene Therapy, Vol. 18, pp. 806–816.10.1038/cgt.2011.50 ↗
89. 89) Kubo, T., Toyooka, S., Tsukuda, K., Sakaguchi, M., Fukazawa, T., Soh, J., Asano, H., Ueno, T., Muraoka, T., Yamamoto, H., Nasu, Y., Kishimoto, T., Pass, H. I., Matsui, H., Huh, N. H. and Miyoshi, S. (2011): Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma, Clinical Cancer Research, Vol. 17, pp. 4965–4974.10.1158/1078-0432.CCR-10-3040 ↗
90. 90) Ghawanmeh, T., Thunberg, U., Castro, J., Murray, F. and Laytragoon-Lewin, N. (2011): miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment, Oncology, Vol. 81, pp. 330–335.10.1159/000334237 ↗
91. 91) Ivanov, S. V., Goparaju, C. M., Lopez, P., Zavadil, J., Toren-Haritan, G., Rosenwald, S., Hoshen, M., Chajut, A., Cohen, D. and Pass, H. I. (2010): Pro-tumorigenic effects of miR-31 loss in mesothelioma, Journal of Biological Chemistry, Vol. 285, pp. 22809–22817.10.1074/jbc.M110.100354 ↗
92. 92) Balatti, V., Maniero, S., Ferracin, M., Veronese, A., Negrini, M., Ferrocci, G., Martini, F. and Tognon, M. G. (2011): MicroRNAs dysregulation in human malignant pleural mesothelioma, Journal of Thoracic Oncology, Vol. 6, pp. 844–851.10.1097/JTO.0b013e31820db125 ↗
93. 93) Guled, M., Lahti, L., Lindholm, P. M., Salmenkivi, K., Bagwan, I., Nicholson, A. G. and Knuutila, S. (2009): CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma - A miRNA microarray analysis, Genes, Chromosomes & Cancer, Vol. 48, pp. 615–623.10.1002/gcc.20669 ↗
94. 94) Nymark, P., Guled, M., Borze, I., Faisal, A., Lahti, L., Salmenkivi, K., Kettunen, E., Anttila, S. and Knuutila, S. (2011): Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer, Genes, Chromosomes & Cancer, Vol. 50, pp. 585–597.10.1002/gcc.20880 ↗